Figure 1. The timeline of the patient’s absolute eosinophil counts over 36 months since eosinophilia onset. Pharmacological management and significant events are denoted by the letters A - I.
| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website https://jmc.elmerpub.com |
Case Report
Volume 000, Number 000, August 2025, pages 000-000
Benralizumab in a Patient With Refractory Eosinophilic Endocarditis
Figure
Table
| Month since eosinophilia onset | Absolute eosinophil count (cells/µL) | Treatment | |
|---|---|---|---|
| 12 | A | 20,400 | Prednisone 60 mg orally daily, then hydroxyurea 1,000 mg orally daily, then prednisone 80 mg orally daily + hydroxyurea 2,000 mg orally daily |
| 14 | B | 29,300 | Prednisone 80 mg orally daily + mepolizumab 100 mg subcutaneously every 4 weeks |
| 15 | C | 47,300 | Ivermectin orally × 1 dose + mepolizumab 100 mg subcutaneously every 4 weeks |
| 16 | D | 53,000 | Imatinib 400 mg orally daily |
| 23 | E | 38,900 | Methotrexate 10 mg/m2 orally weekly |
| 24 | F | 82,800 | Hydroxyurea 4,000 mg orally daily |
| 25 | G | 5,800 | Hydroxyurea 1,000 mg orally daily + mepolizumab 300 mg subcutaneously every 4 weeks |
| 28 | H | 10,800 | Off-label benralizumab 30 mg subcutaneously every 4 weeks |
| 29 | I | 0 | Off-label benralizumab 30 mg subcutaneously every 8 weeks with plans to be continued indefinitely |